Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis
- 15 June 2004
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 116 (12) , 816-828
- https://doi.org/10.1016/j.amjmed.2004.01.017
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Thrombophilia testingJournal of Thrombosis and Haemostasis, 2003
- Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness AnalysisMedical Decision Making, 2002
- Genetic Susceptibility to Venous ThrombosisNew England Journal of Medicine, 2001
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationNew England Journal of Medicine, 1999
- Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C ResistanceArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Laboratory Diagnosis of Hereditary ThrombophiliaSeminars in Thrombosis and Hemostasis, 1998
- Screening Tests for Thrombophilic Patients: Which Tests, for Which Patient, by Whom, When, and Why?Seminars in Thrombosis and Hemostasis, 1998
- Long-term outcomes after deep venous thrombosis of the lower extremitiesVascular Medicine, 1998
- Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosisLupus, 1996
- Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study*1The Lancet, 1994